Biodesix (BDSX) Q2 2026 earnings review
Strong Volume Growth Masks Ongoing Shareholder Dilution
Biodesix delivered robust 34% YoY revenue growth in Q2, driven by a 38% surge in diagnostic test volumes as its primary care expansion strategy continues to pay off. Operating leverage was excellent, with operating expenses growing just 7%. However, the core concern remains capital structure: despite significant margin improvements, the company posted a $3.2 million Adjusted EBITDA loss and continues to rely heavily on its At-The-Market (ATM) facility to fund operations, raising $6.5M in Q2 on top of $16.8M in Q1. While management maintained full-year guidance, the 'path to profitability' is forcing painful dilution on existing shareholders.
🐂 Bull Case
Gross margins hit 82% (up 200 bps YoY), and operating expenses excluding direct costs grew only 7% while revenues grew 34%. This proves the core testing business is highly scalable once sales reps ramp up.
Core diagnostic testing revenue grew 42% YoY to $25.4 million, fueled by a 38% jump in test volumes (20,900 tests). The strategic shift into the primary care channel is clearly working and capturing a larger piece of the lung nodule market.
🐻 Bear Case
The company cannot fund its own growth yet. Weighted-average shares outstanding surged 40% YoY (from 7.33M to 10.3M) due to constant ATM usage. Revenue growth means little if the equity base is continually diluted.
Development Services revenue fell 28% YoY to $1.5M. While management cites 'timing of project completion,' this segment remains historically lumpy and highly unpredictable.
⚖️ Verdict: ⚪
Neutral. The operational execution in the core diagnostics business is stellar, and gross margins are impressive. But until Biodesix can fully cross the break-even threshold without diluting shareholders via ATM stock sales every quarter, it remains a 'show-me' story for value creation.
Key Themes
Primary Care Expansion Driving Volume
Diagnostic Testing revenue growth of 42% is the engine of the company, fueled entirely by a 38% increase in test volumes (20,900 tests vs 15,100 in 25Q2). The expansion into the primary care physician (PCP) channel—which manages nearly 50% of incidental lung nodules—is translating into accelerating market penetration.
Textbook Operating Leverage
The margin profile is accelerating. Total revenue grew 34%, while operating expenses (excluding direct costs) increased just 7% to $27.4 million. Gross margins expanded 200 bps to 82%. This demonstrates that the company's prior investments in laboratory workflow optimization and sales force expansion are finally yielding unit economic benefits.
Improving ASP via Revenue Cycle Management
Management noted that the remaining gap between the 38% volume growth and 42% diagnostic revenue growth was driven by higher average revenue per test (ASP). Expanded payer coverage and structural improvements to billing are holding steady and converting more tests to actual cash.
Clinical Evidence Engine
Biodesix continues to point to expanded clinical evidence supporting the Nodify Lung tests as a core growth driver. By consistently publishing real-world data (like the CLARIFY study mentioned in prior quarters), they are building the necessary moats for both physician adoption and payer reimbursement.
Heavy Reliance on Share Dilution
A severe contradiction exists between the 'path to profitability' narrative and capital structure actions. The company reported $30.0 million in cash, up 17% sequentially, but this was exclusively driven by $6.5 million in net proceeds from the ATM program. Weighted-average shares outstanding spiked to 10.3 million from 7.3 million a year ago. Existing shareholders are footing the bill for this growth.
Development Services Segment Reversing
After nearly doubling YoY in Q1 2026 (largely due to a pull-forward of retrospective samples), Development Services revenue contracted 28% YoY in Q2 to $1.5 million. Management called the pipeline 'strong' and blamed 'timing of project completion,' but this segment's lumpiness complicates overall revenue predictability.
The Breakeven Mirage
The company celebrated its first positive Adjusted EBITDA quarter in Q4 2025 ($0.5M). Since then, it has posted two consecutive quarters of negative Adjusted EBITDA (-$4.1M in Q1, -$3.2M in Q2). While YoY comparisons show improvement, the sequential failure to maintain positive profitability is a point for close monitoring.
Other KPIs
Accelerating. Up 200 basis points from Q2 2025. This was driven by higher diagnostic testing volumes, improved ASPs, and laboratory workflow optimization lowering the cost per test. This elite margin profile is the bedrock of the bullish thesis.
Stable improvement YoY (56% better than -$7.2M in Q2 2025), but represents a continued cash bleed. Until this metric crosses back into positive territory consistently, capital raises will remain a looming threat.
Stable. The term loan remains the primary piece of leverage on the balance sheet. Cash stands at $30.0M, but net debt remains negative. Managing interest expense ($2.0M this quarter) while burning cash from operations is an ongoing headwind.
Guidance
Stable. The company maintained its prior guidance. The midpoint ($111M) represents approximately 25% YoY growth. Achieving this will require the core diagnostic testing volume to remain elevated, offsetting any further weakness in Development Services.
Stable. The company continues to expect gross margins to hold near 80% for the full year, indicating that the 82-84% seen in H1 2026 might face some seasonal or mix-driven compression in H2.
Key Questions
ATM Utilization Strategy
With $6.5 million raised via ATM this quarter after $16.8 million in Q1, at what specific cash floor or Adjusted EBITDA target will the company cease tapping the equity markets and halting dilution?
Development Services Visibility
Given the 28% YoY decline in Development Services this quarter, what is the exact dollar amount of the contracted backlog expected to convert to revenue in H2 2026?
Sales Rep Productivity Cohorts
Are the sales reps hired in late 2025 achieving the target $1 million annualized productivity rate, and what percentage of current diagnostic volume is coming from reps with less than 12 months of tenure?
Sustained EBITDA Positivity
After briefly turning Adjusted EBITDA positive in Q4 2025, the company has regressed in H1 2026. What quarter does management realistically target for crossing the breakeven line and staying there permanently?